What is B. Riley’s Estimate for Immunic Q1 Earnings?

Immunic, Inc. (NASDAQ:IMUX) – B. Riley issued their Q1 2026 earnings per share (EPS) estimates for shares of Immunic in a research note issued on Tuesday, November 25th. B. Riley analyst W. Wood expects that the company will post earnings per share of ($0.10) for the quarter. The consensus estimate for Immunic’s current full-year earnings is ($0.94) per share. B. Riley also issued estimates for Immunic’s Q2 2026 earnings at ($0.10) EPS, Q3 2026 earnings at ($0.10) EPS and Q4 2026 earnings at ($0.10) EPS.

IMUX has been the topic of a number of other reports. D. Boral Capital lowered their target price on shares of Immunic from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Thursday, November 13th. Chardan Capital upgraded shares of Immunic to a “strong-buy” rating in a research note on Wednesday, November 19th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Immunic in a report on Tuesday. LADENBURG THALM/SH SH upgraded shares of Immunic to a “strong-buy” rating in a research note on Thursday, October 16th. Finally, HC Wainwright lowered their price target on Immunic from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Friday, November 14th. Two research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $7.40.

Immunic Stock Down 0.8%

Shares of Immunic stock opened at $0.70 on Wednesday. The stock has a market cap of $84.32 million, a P/E ratio of -0.75 and a beta of 1.53. Immunic has a 12-month low of $0.56 and a 12-month high of $1.42. The business’s 50 day moving average is $0.81 and its 200-day moving average is $0.84.

Immunic (NASDAQ:IMUX) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.05.

Institutional Investors Weigh In On Immunic

Hedge funds have recently bought and sold shares of the stock. Qube Research & Technologies Ltd bought a new stake in shares of Immunic during the third quarter worth approximately $29,000. Two Sigma Investments LP acquired a new stake in Immunic during the 3rd quarter worth approximately $52,000. HB Wealth Management LLC bought a new stake in Immunic in the 3rd quarter valued at $81,000. Virtu Financial LLC bought a new stake in Immunic in the 3rd quarter valued at $99,000. Finally, GSA Capital Partners LLP acquired a new position in Immunic in the 3rd quarter valued at $170,000. 51.82% of the stock is currently owned by institutional investors and hedge funds.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.